<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962984</url>
  </required_header>
  <id_info>
    <org_study_id>CPRC 2017/TG THAL-MARTIN/MS</org_study_id>
    <nct_id>NCT04962984</nct_id>
  </id_info>
  <brief_title>Thrombin Generation in Beta-thalassemia Major</brief_title>
  <acronym>TG-THAL</acronym>
  <official_title>Evaluation of Hypercoagulability by Thrombin Generation Test in Beta-thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the persistence of a hypercoagulable state in&#xD;
      chronically-transfused patients with beta thalassemia major, by using the thrombin generation&#xD;
      test (performed in whole blood and plasma). Patients will be compared with 2 control groups:&#xD;
      1/ healthy volunteers and 2/ carriers of beta-thalassemia trait&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of hypercoagulability using endogenous thrombin potential (ETP) between patients and controls</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of the area under the thrombin generation curve (ie ETP) in THAL+ patients, before and after transfusion, as compared with ETP measured in controls groups (THAL- and healthy volunteers)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of endogenous thrombin potential's variations before and after transfusion in THAL+ patients over 3 transfusion episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of the area under the thrombin generation curve before and after transfusion in THAL+ patients over 3 transfusion episodes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Beta Thalassemia Major Anemia</condition>
  <arm_group>
    <arm_group_label>THAL +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THAL -</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>additional blood sampling for coagulation tests</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>THAL +</arm_group_label>
    <arm_group_label>THAL -</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with de Beta-thalassemia major&#xD;
&#xD;
          -  Patient with regular blood transfusion regimen (every 4 - 6 weeks)&#xD;
&#xD;
          -  informed and signed consent&#xD;
&#xD;
          -  weight &gt; 30kg&#xD;
&#xD;
          -  Hemoglobin &gt; 7g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency situation&#xD;
&#xD;
          -  Patients receiving antithrombotic drugs (anticoagulants such as Vitamin K antagonism,&#xD;
             heparin or direct oral anticoagulant) or antiplatelet drugs;&#xD;
&#xD;
          -  women of childbearing age without contraception&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  deprivation of liberty&#xD;
&#xD;
          -  no consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beta Thalassemia Major; hypercoagulability; thrombin generation test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

